Anti-CD38 Antibody Combination Therapy for B-cell Malignancies

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies have limited efficacy, particularly in high-risk groups, with survival rates as low as 30% over five years, necessitating the development of more effective combination therapies.

Innovation Solution

Administering an anti-CD38 antibody in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to induce killing of CD38-expressing cells through antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, complement-dependent cytotoxicity, apoptosis, or modulation of CD38 enzymatic activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If standard CHOP chemotherapy is used to treat B-cell malignancies, then treatment can be administered with existing protocols, but treatment efficacy is limited particularly in high-risk groups with survival rates as low as 30% over five years

Engineering Contradiction:

Improvetreatment efficacyVSAvoidlimited efficacy in high-risk groups

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines anti-CD38 antibody therapy with standard CHOP chemotherapy regimen to create a combination therapy that targets multiple pathways simultaneously. The anti-CD38 antibody specifically targets CD38-expressing B-cell malignancies while CHOP provides broad chemotherapy coverage, creating synergistic anti-tumor effects that improve survival rates compared to CHOP alone

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent introduces a new therapeutic parameter (anti-CD38 antibody targeting) to the existing CHOP treatment protocol. By adding this specific biological target with different mechanism of action, the treatment regimen transitions from conventional chemotherapy alone to a combined approach that addresses limitations of single-modality therapy

Inventive Principle:

Principle #35Parameter changes

2Reliability

If combination therapy with anti-CD38 antibody and CHOP is administered, then treatment efficacy and survival rates improve, but treatment complexity increases

Engineering Contradiction:

Improvesurvival ratesVSAvoidtreatment regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The combination therapy is administered in a segmented manner, with anti-CD38 antibody given every 2 weeks and CHOP chemotherapy administered in cycles. This segmentation allows each agent to be optimized independently while maintaining manageable treatment scheduling that reduces complexity burden on patients

Inventive Principle:

Principle #1Segmentation

3Productivity

If anti-CD38 antibody is added to CHOP regimen, then tumor growth inhibition is enhanced through synergistic potency, but treatment cost and administration complexity increase

Engineering Contradiction:

Improvetumor growth inhibitionVSAvoidadministration complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The anti-CD38 antibody is administered periodically every 2 weeks, allowing accumulation of therapeutic effect while maintaining manageable treatment frequency. This periodic administration schedule enables synergistic tumor growth inhibition when combined with CHOP cycles, while keeping the treatment rhythm manageable for patients

Inventive Principle:

Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination therapy demonstrates synergistic potency in relevant tumor models, leading to significant tumor growth inhibition and improved survival rates, with the anti-CD38 antibody enhancing the efficacy of CHOP or R-CHOP regimens.

Implementation Method 1

the anti-CD38 antibody induces killing of CD38-expressing cells in vitro by antibody-dependent cell-mediated cytotoxicity (ADCC)

Methodology Applied

Scientific EffectAntibody-dependent cell-mediated cytotoxicity:

Implementation Method 2

antibody-dependent cellular phagocytosis (ADCP)

Methodology Applied

Scientific EffectAntibody-dependent cellular phagocytosis:

Implementation Method 3

complement dependent cytotoxicity (CDC)

Methodology Applied

Scientific EffectComplement-dependent cytotoxicity:

Implementation Method 4

apoptosis

Methodology Applied

Scientific EffectApoptosis:

Implementation Method 5

modulation of CD38 enzymatic activity

Methodology Applied

Scientific EffectEnzymatic activity modulation: Enzyme

Data Source

PatentUS20250011457A1Combination Therapies with Anti-CD38 Antibodies

Publication Date: 2025.01.09 JANSSEN BIOTECH INC

AI summary

The present invention relates to combination therapies with anti-CD38 antibodies.